Neoadjuvant treatment sequencing adds value to the care of patients with operable pancreatic cancer

Authors:
Publisher website
Google Scholar
Abstract
Treatment sequencing for resectable pancreatic cancer remains controversial and there is lack of level one evidence comparing neoadjuvant versus adjuvant strategies. However, a comparison of the cost‐effectiveness analysis of the treatment strategies may help to better define the healthcare value of each approach. This review will highlight the rationale for multimodality therapy in the treatment of pancreatic cancer, discuss the advantages and disadvantages of adjuvant therapy, and conceptualize the cost‐effectiveness of a neoadjuvant approach with regard to healthcare value. J. Surg. Oncol. 2016;114:291–295.

This publication has 22 references indexed in Scilit: